NCT05029401 - A Study of Oral Ibogaine in Opioid Withdrawal | Biotech Hunter

Enrollment

116

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

January 16, 2024

Study Completion Date

January 16, 2024

Conditions

Opiate Withdrawal Syndrome

Interventions

DRUG

DMX-1002

Investigation of the safety, tolerability and pharmacokinetics (PK) in healthy volunteers (Stage 1 - single blind), and the efficacy, safety, tolerability and PK in opioid-dependent patients (Stage 2 - double blind)

DRUG

Placebo

Matching placebo to the IMP (DMX-1002)

Trial Locations (2)

M13 9NQ

MAC Clinical Research Manchester (Early Phase Unit), Neuroscience Centre of Excellence, Manchester

NW10 7EW

Hammersmith Medicines Research (HMR) Limited, London